Dr. Borghaei on the FDA Approval of Nivolumab in Small Cell Lung Cancer
Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the FDA approval of nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.
Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the FDA approval of nivolumab (Opdivo) for the treatment of patients with small cell lung cancer (SCLC) with disease progression following 2 or more lines of therapy.
Click to read more on the
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”September 15th 2025
Annaiz Grimm, BS, on Using EngTregs to Treat Autoimmune DiseaseAugust 28th 2025
